GLP-1 Receptor Agonists for PCOS: Weight Loss, Insulin Resistance, and Hormonal Outcomes

Is any GLP-1 drug approved for PCOS?

PCOS is not an FDA-approved indication for any GLP-1 receptor agonist. The product labels list type 2 diabetes, weight management, cardiovascular risk reduction, kidney outcomes in type 2 diabetes with CKD, MASH and sleep apnea, depending on the product [1][2][3][4]. Semaglutide appears as Ozempic for type 2 diabetes and Wegovy for weight management and cardiovascular risk reduction [1][10]. Liraglutide appears as Victoza for type 2 diabetes and Saxenda for weight management [11][3]. Tirzepatide is labeled as Mounjaro for type 2 diabetes and Zepbound for weight management and sleep apnea [4][12]. Orforglipron (Foundayo) is an oral GLP-1 receptor agonist labeled for weight management [2].

If a GLP-1 drug is used for PCOS, that use is off-label. The labels do not include PCOS, and they do not give a PCOS-specific dose [1][2][3][4].

What is PCOS and why do GLP-1 drugs get used?

PCOS is a common hormonal disorder; WHO estimates 10–13% of reproductive-aged women have it [13]. Diagnosis uses at least two of: clinical or biochemical hyperandrogenism, irregular or absent periods, and polycystic ovaries, after other causes are excluded [13]. PCOS is associated with insulin resistance, which can drive hyperandrogenism, and with higher long-term risk of type 2 diabetes and obesity [14][13]. A meta-analysis of 40 quality studies found higher odds of impaired glucose tolerance (OR 3.26, 95% CI 2.17-4.90) and type 2 diabetes (OR 2.87, 95% CI 1.44-5.72) in women with PCOS [9].

GLP-1 receptor agonists activate the GLP-1 receptor. Labels describe GLP-1 as a regulator of appetite and caloric intake, with receptors in brain areas that regulate appetite; semaglutide also stimulates insulin secretion, lowers glucagon in a glucose-dependent manner and delays gastric emptying [1]. Tirzepatide adds GIP receptor activity, so it is a dual agonist rather than a pure GLP-1 agonist [4]. PCOS itself is not a labeled use [1][4][6].

What does the PCOS-specific evidence show?

The main PCOS-specific synthesis is a 2019 systematic review and meta-analysis of 8 randomized trials comparing GLP-1 receptor agonists with metformin [5]. GLP-1 receptor agonists were more effective for insulin sensitivity (standardized mean difference -0.40, 95% CI -0.74 to -0.06; P=0.02), BMI (standardized mean difference -1.02, 95% CI -1.85 to -0.19; P=0.02) and abdominal girth (standardized mean difference -0.45, 95% CI -0.89 to -0.00; P=0.05) [5]. Nausea and headache were more common with GLP-1 receptor agonists; the authors reported no significant differences for the other outcomes they analyzed and rated the evidence moderate to low quality [5].

A 2020 narrative review focused on liraglutide, used alone or with metformin, in women with obesity and PCOS. It reported significant weight loss and testosterone reduction in several studies, with mixed results for insulin resistance parameters and menstrual patterns [6].

The meta-analysis compared GLP-1 receptor agonists with metformin; it did not test GLP-1 receptor agonists added to metformin [5].

What about semaglutide and tirzepatide in PCOS?

The semaglutide and tirzepatide trials below enrolled adults by obesity or overweight criteria, not by PCOS status [7][8]. In STEP 1, 1,961 adults with obesity or overweight and no diabetes lost 14.9% of body weight with semaglutide 2.4 mg weekly versus 2.4% with placebo at 68 weeks [7]. In SURMOUNT-1, 2,539 adults with obesity or overweight and no diabetes lost 15.0%, 19.5% and 20.9% with tirzepatide 5, 10 and 15 mg versus 3.1% with placebo at 72 weeks [8]. In SURMOUNT-5, 751 adults with obesity lost 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks [15].

Semaglutide is a selective GLP-1 receptor agonist; tirzepatide activates both GIP and GLP-1 receptors [1][4].

What safety issues matter with GLP-1 drugs?

The Wegovy, Saxenda, Zepbound and Foundayo labels carry a boxed warning for thyroid C-cell tumors seen in rodents; human relevance is unknown, and the drugs are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 [1][3][4][2]. Labels also list acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from volume depletion, acute gallbladder disease, hypoglycemia when combined with insulin or a sulfonylurea, serious hypersensitivity, diabetic retinopathy complications in type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation [1][2]. The Wegovy label says it is not recommended in severe gastroparesis [1].

Common GI effects are most frequent during dose escalation. With Wegovy 2.4 mg, nausea occurred in 44%, diarrhea in 30%, vomiting in 24% and constipation in 24%, versus 16%, 16%, 6% and 11% with placebo; hair loss occurred in 3% versus 1% [1]. With Foundayo 17.2 mg, nausea occurred in 35%, constipation in 24%, diarrhea in 25% and vomiting in 24%, versus 10%, 9%, 11% and 4% with placebo [2]. Rates from different trials are not directly comparable [1][2].

What do the labels say about pregnancy and contraception?

The Wegovy label says to discontinue when pregnancy is recognized for weight or cardiovascular use, and at least 2 months before a planned pregnancy because of semaglutide's long half-life [1]. The Foundayo label says to discontinue when pregnancy is recognized and advises switching from oral contraceptives to a non-oral method or adding a barrier method for 30 days after starting and after each dose escalation [2]. The tirzepatide label gives similar advice for 4 weeks after starting and after each dose increase [4]. Semaglutide labels carry no such oral-contraceptive advice; a tablet interaction study found no clinically significant change in ethinyl estradiol or levonorgestrel [1].